RET and neoplasm: In the RAS wild-type cohort (n=9), 3/4 patients with BRAF Class II alterations and 1/4 patients with RET rearrangements qualified for RAI, with 3 SDs and 1 PR (in patient with a BRAF-altered tumor) (117).